TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06216158
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
Study: NCT05962229
Drug: (S)-Nicotine
Normalized name: (S)-Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
Study: NCT05962229
Drug: (R)- nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
Study: NCT05962229
Drug: Racemic nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
Study: NCT05968846
Drug: Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Normalized name: povidone-iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
Study: NCT04700423
Drug: moxidectin (8 mg) / albendazole (400 mg)
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Study: NCT04700423
Drug: ivermectin (200 µg/kg) / albendazole (400 mg)
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Study: NCT04700423
Drug: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
Normalized name: ALBENDAZOLE 400 mg ORAL TABLET [ZENTEL]
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
Study: NCT04700423
Drug: ivermectin (200 µg/kg)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
Study: NCT04700423
Drug: moxidectin (8 mg)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
Study: NCT06280209
Drug: BMN 351
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
Study: NCT00000438
Drug: naltrexone (Revia)
Normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04961905
Drug: NVP-2002-R1+NVP-2002-R2
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
Study: NCT04961905
Drug: NVP-2002
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily
Study: NCT06571344
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.
Study: NCT05945888
Drug: BI 3000202
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 3000202
Study: NCT05635227
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See description of arms
Study: NCT06254066
Drug: Adebrelimab plus Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
Study: NCT00002219
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002219
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002217
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002217
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002217
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05635227
Drug: Isotonic sodium chloride (0.9%)
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See description of arms
Study: NCT05635227
Drug: Olanzapine 10 MG
Normalized name: olanzapine 10 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
Study: NCT05049863
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil is commercially available.
Study: NCT05049863
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol is commercially available.
Study: NCT05049863
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan is commercially available.
Study: NCT05236036
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05236036
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given Orally (PO)
Study: NCT06135584
Drug: Pioglitazone metformin tablets
Normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
Study: NCT01245725
Drug: Tirofiban (Aggrastat)
Normalized name: tirofiban Injection [Aggrastat]
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion.
Study: NCT05100134
Drug: ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive ceritinib
Study: NCT04655157
Drug: encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
Study: NCT04655157
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
Study: NCT04655157
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Study: NCT04655157
Drug: binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study: NCT05195112
Drug: MT921
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active ingredient
Study: NCT06513533
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
Study: NCT06433479
Drug: Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
Study: NCT05776758
Drug: cisplatin based neoadjuvant chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin based neoadjuvant chemotherapy
Study: NCT05476081
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study: NCT05476081
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study: NCT05476081
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study: NCT06645886
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral dasatinib
Study: NCT06709079
Drug: Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)
Normalized name: Green tea leaf
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
Study: NCT06716164
Drug: Metabolically Armed CD19 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
Study: NCT05779657
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
Study: NCT05779657
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
Study: NCT04973137
Drug: Birtamimab
Normalized name: Birtamimab
DrugBank: Birtamimab (DB16414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 24 mg/kg birtamimab every 28 days
Study: NCT05624268
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMP360 Psilocybin administered under supportive conditions
Study: NCT06360419
Drug: Solriamfetol 300 mg
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solriamfetol tablets, taken once daily
Study: NCT06635902
Drug: L-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
Study: NCT05832892
Drug: surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib.
Study: NCT05832892
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
Study: NCT05832892
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
Study: NCT05832892
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
Study: NCT06635902
Drug: L-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
Study: NCT06344637
Drug: 10 % lidocaine spray without adrenaline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
Study: NCT05035888
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT04258852
Drug: Low strength nicotine e-liquid
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low strength nicotine e-liquid
Study: NCT04258852
Drug: High strength nicotine e-liquid
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High strength nicotine e-liquid
Study: NCT04941105
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single subcutaneous administration of 140 mg evolocumab
Study: NCT04941105
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single subcutaneous injection of 1ml of 0,9% saline solution
Study: NCT00051077
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00051077
Drug: Peginterferon-alfa-2A
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00051077
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05983094
Drug: Utidelone
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utidelone injection 30mg/m2, on days 1-5 of each cycle
Study: NCT05983094
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin Area under curve(AUC)6, iv, was administered on day 1
Study: NCT05983094
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 75mg/m2 was administered on day 1
Study: NCT05983094
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
Study: NCT05983094
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
Study: NCT05203380
Drug: dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
Study: NCT05775900
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
Study: NCT05175274
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5mg/tablet
Study: NCT06206850
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
Study: NCT06301503
Drug: USG Guided Combined LPB-SNB with Isobaric Bupivacaine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
Study: NCT06301503
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic infiltration of 2% lidocaine (3ml)
Study: NCT05495581
Drug: pudexacianinium chloride
Normalized name: CHLORIDE
DrugBank: Pudexacianinium (DB19161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT05658575
Drug: Dapansutrile
Normalized name: Dapansutrile
DrugBank: Dapansutrile (DB16130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
Study: NCT05930080
Drug: SKCPT
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the randomly assigned subjects took the study drug for 12 weeks
Study: NCT05930080
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the randomly assigned subjects took the study drug for 12 weeks
Study: NCT03885141
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem or Placebo if there is a wake up during the night
Study: NCT04575519
Drug: SoC TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Tuberculosis treatment
Study: NCT06341400
Drug: DisitamabVedotinForIicction Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
Study: NCT04445662
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement
Study: NCT05081921
Drug: MesoCellA-Ortho administration
Normalized name: Ortho-Nesic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups.
Study: NCT04853927
Drug: Proxalutamide
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 300mg q.d suspension
Study: NCT06482086
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
Study: NCT06482086
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8/12 mg qd, po.
Study: NCT06482086
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 g bid, po.
Study: NCT06482086
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g bid, po.
Study: NCT06482086
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg qd, po.
Study: NCT06482086
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg qd, po.
Study: NCT06482086
Drug: Dabrafenib + Trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
Study: NCT06482086
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib 60mg qd, po.
Study: NCT06482086
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 300mg qd, po.